Axogen Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Public

  • Employees
  • 428


  • Stock Symbol
  • AXGN

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $7.15
  • (As of Tuesday Closing)

Axogen General Information


Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Contact Information

Formerly Known As
Lectec Corp
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Other Healthcare Services
Stock Exchange
Corporate Office
  • 13631 Progress Boulevard
  • Suite 400
  • Alachua, FL 32615
  • United States
+1 (888) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Axogen Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$7.15 $7.41 $3.45 - $10.83 $312M 43.7M 314K -$0.50

Axogen Financials Summary

In Thousands,
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 390,828 328,801 436,561 366,905
Revenue 163,726 159,012 138,584 127,358
EBITDA (9,927) (13,328) (23,471) (20,888)
Net Income (21,277) (21,716) (28,948) (26,985)
Total Assets 186,516 196,827 195,387 208,024
Total Debt 69,150 69,292 67,427 67,453
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Axogen Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Axogen‘s full profile, request access.

Request a free trial

Axogen Patents

Axogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240009348-A1 Multi-layer amnion product, related devices, and related methods Pending 08-Jul-2022 000000000
US-20230346368-A1 Sutureless connectors and methods of preparing and using same Pending 27-Apr-2022 000000000000
US-20240050089-A1 Sutureless connector and methods of preparing and using same Pending 27-Apr-2022 000000000000
US-20230201577-A1 Electrode apparatus for tissue stimulation and related method of use Pending 28-Dec-2021 0000000000
US-20230200966-A1 Tissue wrap device with attachment features Pending 28-Dec-2021 A61F2/0077
To view Axogen’s complete patent history, request access »

Axogen Executive Team (20)

Name Title Board Seat Contact Info
Karen Zaderej Chief Executive Officer & Chairman
Nir Naor Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Jens Schrøder Kemp Chief Marketing Officer
Erick DeVinney Vice President
Ivica Ducic MD Chief Medical Officer
You’re viewing 5 of 20 executive team members. Get the full list »

Axogen Board Members (16)

Name Representing Role Since
Alan Levine Self Board Member 000 0000
Amy Wendell Axogen Board Member 000 0000
Gregory Freitag JD Self Board Member 000 0000
Guido Neels EW Healthcare Partners Board Member 000 0000
Karen Zaderej Axogen Chief Executive Officer & Chairman 000 0000
You’re viewing 5 of 16 board members. Get the full list »

Axogen Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Axogen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Axogen‘s full profile, request access.

Request a free trial

Axogen Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Lectec 30-Sep-2011 0000000000 0000 Drug Delivery 00000 000
To view Axogen’s complete acquisitions history, request access »

Axogen Subsidiaries (1)

Company Name Industry Location Founded
Lectec Drug Delivery Texarkana, TX 0000
To view Axogen’s complete subsidiaries history, request access »

Axogen ESG

Risk Overview

Risk Rating

Updated April, 27, 2024

27.75 | Med Risk

Risk Scale

A lower score indicates better sustainability












Exposure refers to the extent to which a company is exposed to different material ESG issues



Management is related to actions taken to manage ESG issues


Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.


Covered Companies

00 of 16,191






00 of 643




Medical Devices


00 of 229




To view Axogen’s complete esg history, request access »

Axogen FAQs

  • When was Axogen founded?

    Axogen was founded in 2002.

  • Who is the founder of Axogen?

    John Engels is the founder of Axogen.

  • Who is the CEO of Axogen?

    Karen Zaderej is the CEO of Axogen.

  • Where is Axogen headquartered?

    Axogen is headquartered in Alachua, FL.

  • What is the size of Axogen?

    Axogen has 428 total employees.

  • What industry is Axogen in?

    Axogen’s primary industry is Biotechnology.

  • Is Axogen a private or public company?

    Axogen is a Public company.

  • What is Axogen’s stock symbol?

    The ticker symbol for Axogen is AXGN.

  • What is the current stock price of Axogen?

    As of 18-Jun-2024 the stock price of Axogen is $7.15.

  • What is the current market cap of Axogen?

    The current market capitalization of Axogen is $312M.

  • What is Axogen’s current revenue?

    The trailing twelve month revenue for Axogen is $164M.

  • What is Axogen’s annual earnings per share (EPS)?

    Axogen’s EPS for 12 months was -$0.50.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »